[go: up one dir, main page]

MX2016008442A - Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno. - Google Patents

Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno.

Info

Publication number
MX2016008442A
MX2016008442A MX2016008442A MX2016008442A MX2016008442A MX 2016008442 A MX2016008442 A MX 2016008442A MX 2016008442 A MX2016008442 A MX 2016008442A MX 2016008442 A MX2016008442 A MX 2016008442A MX 2016008442 A MX2016008442 A MX 2016008442A
Authority
MX
Mexico
Prior art keywords
fgf
hydrogels
alginate
formulation
collagen hydrogels
Prior art date
Application number
MX2016008442A
Other languages
English (en)
Other versions
MX368970B (es
Inventor
CANAL Fabiana
Lo Presti Caterina
Original Assignee
Ares Trading Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading Sa filed Critical Ares Trading Sa
Publication of MX2016008442A publication Critical patent/MX2016008442A/es
Publication of MX368970B publication Critical patent/MX368970B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/505—Stabilizers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/06—Flowable or injectable implant compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Polymers & Plastics (AREA)

Abstract

La invención se refiere al campo de las formulaciones farmacéuticas; más en particular, está dirigida a hidrogeles homogéneos que comprenden un compuesto de factor de crecimiento de fibroblasto 18 (FGF-18) y a métodos de producción de dichos hidrogeles; los hidrogeles de la invención se pueden usar, una vez formados in situ, para el tratamiento de trastornos del cartílago como osteoartritis o lesión del cartílago.
MX2016008442A 2013-12-24 2014-12-23 Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno. MX368970B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13199591 2013-12-24
PCT/EP2014/079205 WO2015097236A2 (en) 2013-12-24 2014-12-23 Fgf-18 formulation in alginate/collagen hydrogels

Publications (2)

Publication Number Publication Date
MX2016008442A true MX2016008442A (es) 2017-01-11
MX368970B MX368970B (es) 2019-10-23

Family

ID=49882942

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008442A MX368970B (es) 2013-12-24 2014-12-23 Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno.

Country Status (16)

Country Link
US (1) US9795714B2 (es)
EP (1) EP3086822B1 (es)
JP (1) JP6487448B2 (es)
KR (1) KR102434024B1 (es)
CN (1) CN106068131B (es)
AU (1) AU2014372578B2 (es)
BR (1) BR112016014717B1 (es)
CA (1) CA2934638C (es)
ES (1) ES2806026T3 (es)
IL (1) IL246407B (es)
MX (1) MX368970B (es)
NZ (1) NZ721597A (es)
RU (1) RU2698210C2 (es)
SG (1) SG11201604972TA (es)
WO (1) WO2015097236A2 (es)
ZA (1) ZA201604610B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2911888C (en) 2013-02-14 2017-09-19 Nanopareil, Llc Hybrid felts of electrospun nanofibers
SG11201604927RA (en) 2013-12-24 2016-07-28 Ares Trading Sa Fgf-18 formulation in xyloglucan gels
NZ723177A (en) * 2014-02-20 2021-12-24 Merck Patent Gmbh Implant comprising fgf-18
JP6787904B2 (ja) 2015-01-29 2020-11-18 アレス トレーディング ソシエテ アノニム 高度に正に荷電したタンパク質のイムノアッセイ
US10408686B2 (en) * 2016-01-15 2019-09-10 Temptime Corporation Gel-based temperature indicators
US11467169B2 (en) 2017-09-29 2022-10-11 Merck Patent Gmbh Inflammatory biomarkers for predicting responsiveness to FGF-18 compound
US11513128B2 (en) 2017-09-29 2022-11-29 Merck Patent Gmbh Metabolic biomarkers for predicting responsiveness to FGF-18 compound
WO2020010616A1 (zh) * 2018-07-13 2020-01-16 林锡璋 用于内镜手术的组合
CN112513245A (zh) * 2018-08-10 2021-03-16 持田制药株式会社 海藻酸中空微纤维
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
KR102315855B1 (ko) * 2018-11-06 2021-10-22 국립암센터 알긴산 기반의 주입형 수화젤 시스템
CN111068116B (zh) * 2019-12-28 2022-03-22 河北柯瑞生物医药有限公司 一种注射用软骨修复温敏凝胶及其制备方法
WO2021228402A1 (en) * 2020-05-14 2021-11-18 Institut National De La Sante Et De La Recherche Medicale (Inserm) Composite product for the osteoarticular regeneration of cartilage lesion
CN112263505A (zh) * 2020-10-29 2021-01-26 广州栋方生物科技股份有限公司 一种铜肽组合物及其制备方法和应用
CN115990244A (zh) * 2023-03-10 2023-04-21 温州医科大学慈溪生物医药研究院 重组人成纤维细胞生长因子-18蛋白药物组合物对骨质疏松的作用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2254350A1 (en) 1998-11-17 2000-05-17 Hsc Research And Development Limited Partnership Method for bioengineering cartilage
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6355204B1 (en) * 2000-06-07 2002-03-12 Owens-Brockway Plastic Products Inc. Method of manufacturing a dual-chamber container
EP1517698B2 (en) * 2002-06-21 2017-12-06 Novo Nordisk Health Care AG STABILISED SOLID COMPOSITIONS OF FACTOR VIIa POLYPEPTIDES
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
AU2005295927B2 (en) 2004-10-12 2012-02-02 Fmc Biopolymer As Self-gelling alginate systems and uses thereof
US8741326B2 (en) * 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
AU2009237414A1 (en) * 2008-04-14 2009-10-22 Adocia Osteogenic composition including a complex growth factor/amphiphilic polymer, a soluble cation salt, and an organic substrate
JP2011160817A (ja) * 2010-02-04 2011-08-25 Univ Of Tokyo 移植支援材料
PH12013500727A1 (en) 2010-10-15 2013-05-20 Kaken Pharma Co Ltd Sustained-release pharmaceutical composition
US10034737B2 (en) * 2011-02-22 2018-07-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nano-reservoirs technology for use in bone and/or cartilage regeneration
TWI527590B (zh) 2011-06-17 2016-04-01 艾瑞斯貿易公司 Ｆｇｆ－１８之凍乾調配物
SG11201604927RA (en) 2013-12-24 2016-07-28 Ares Trading Sa Fgf-18 formulation in xyloglucan gels

Also Published As

Publication number Publication date
BR112016014717B1 (pt) 2020-12-01
CN106068131B (zh) 2020-01-17
AU2014372578B2 (en) 2018-03-01
JP2017502042A (ja) 2017-01-19
US20160303291A1 (en) 2016-10-20
HK1225657A1 (zh) 2017-09-15
IL246407A0 (en) 2016-08-31
JP6487448B2 (ja) 2019-03-20
EP3086822B1 (en) 2020-04-15
MX368970B (es) 2019-10-23
SG11201604972TA (en) 2016-07-28
CN106068131A (zh) 2016-11-02
NZ721597A (en) 2022-07-01
US9795714B2 (en) 2017-10-24
ZA201604610B (en) 2018-11-28
IL246407B (en) 2020-01-30
AU2014372578A1 (en) 2016-07-14
AU2014372578A2 (en) 2016-11-17
KR102434024B1 (ko) 2022-08-22
CA2934638A1 (en) 2015-07-02
CA2934638C (en) 2022-07-12
ES2806026T3 (es) 2021-02-16
WO2015097236A2 (en) 2015-07-02
EP3086822A2 (en) 2016-11-02
RU2016129817A (ru) 2018-01-30
WO2015097236A3 (en) 2015-09-17
RU2016129817A3 (es) 2018-08-24
KR20160101163A (ko) 2016-08-24
RU2698210C2 (ru) 2019-08-23
BR112016014717A2 (pt) 2017-09-19

Similar Documents

Publication Publication Date Title
MX368970B (es) Formulacion de factor de crecimiento de fibroblastos 18 en hidrogeles de alginato/colageno.
MY170630A (en) Freeze-dried formulations of fgf-18
AU2018260809A1 (en) Compounds and uses thereof for the modulation of hemoglobin
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
EP4371616A3 (en) Compositions of obeticholic acid and methods of use
MX377418B (es) Relleno dérmico a base de acido hialurónico reticulado y lubricante de carboximetilcelulosa.
MX2015011509A (es) Compuestos y usos de estos para la modulacion de la hemoglobina.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
HK1221171A1 (zh) 用於刺激骨生长的组合物
EP3318564A3 (en) Bicyclic heterocycles as fgfr inhibitors
MX2015014234A (es) Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1.
PH12019501199A1 (en) Calcium lactate compositions and methods of use
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
MX2016008441A (es) Formulacion de factor de crecimiento de fibroblastos 18 en geles de xiloglucano.
PH12017501070A1 (en) Peptides and their use in the treatment of skin
WO2016149659A3 (en) Antisense-induced exon exclusion in myostatin
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
NZ723177A (en) Implant comprising fgf-18
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
HK1257498A1 (zh) 在脊髓性肌肉萎缩症中用於内显子纳入的改良的反义寡聚体
PH12015502165A1 (en) Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
PH12017500203A1 (en) Nutritional composition for use in promoting gut and/or liver maturation and/or repair
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
MX383947B (es) Composiciones de colágeno 7 y métodos para usar las mismas.

Legal Events

Date Code Title Description
FG Grant or registration